Compare IDEXX Laboratories, Inc. (IDXX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Wells Fargo & Co — how do they compare? IDEXX Laboratories, Inc. trades at $572.41 (market cap $46.22B), while Wells Fargo & Co trades at $88.64 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 5.7× IDEXX Laboratories, Inc.'s market cap, and Wells Fargo & Co pays a 2.29% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | WFC | |
|---|---|---|
Market Cap | $46.22B | $264.66B |
Sector | Health | Financials |
52-Week High | $766.68 | $96.40 |
52-Week Low | $526.44 | $73.42 |
Enterprise Value | $47.12B | — |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Wells Fargo (WFC) trades at $88.53, up 1.12% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $1.96, beating expectations, and maintains strong profitability with a net income margin of 25.97% and ROE of 13.13%. Recent news highlights the launch of tokenized deposits for corporate clients and a dividend increase to $0.50 per share, reflecting strategic innovation and shareholder returns.
The outlook for WFC is positive, supported by earnings beats, digital banking initiatives, and analyst consensus leaning toward buy. Risks include volatile cash flows, with 2025 operating cash flow negative $19.0B, and competitive pressures in the banking sector. The stock offers value with a P/E of 12.72, below industry averages, but investors should monitor execution on growth strategies and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
